Compare Taiwan Semiconductor Mfg. Co. Ltd. (TSM) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Taiwan Semiconductor Mfg. Co. Ltd. vs Vertex Pharmaceuticals Incorporated — how do they compare? Taiwan Semiconductor Mfg. Co. Ltd. trades at $433.35 (market cap $2.03T), while Vertex Pharmaceuticals Incorporated trades at $521.58 (market cap $134.06B). The key difference: Taiwan Semiconductor Mfg. Co. Ltd. is far larger — about 15.1× Vertex Pharmaceuticals Incorporated's market cap, and Taiwan Semiconductor Mfg. Co. Ltd. pays a 0.94% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| TSM | VRTX | |
|---|---|---|
Market Cap | $2.03T | $134.06B |
Sector | Technology | Health |
52-Week High | $477.57 | $557.96 |
52-Week Low | $258.91 | $376.62 |
Enterprise Value | $1.95T | $128.18B |
Dividend Yield | 0.94% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TSM trades at $439.00, up 2.35% with strong bullish momentum. The stock shows robust fundamentals with 44.56% net margin and consistent earnings beats. Technical indicators signal bullish momentum with price near pivot point support. Recent news highlights TSMC's dominant 73% foundry market share and AI-driven growth prospects, with analyst consensus strongly bullish.
Outlook remains positive with 72% analyst buy ratings and $541.29 price target representing 23% upside. Key risks include geopolitical tensions and capital-intensive expansion, but strong cash flow generation and AI semiconductor demand support continued growth momentum.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with an 86% gross margin and 35% net margin, supported by $12.0B revenue in 2025. Recent acquisition of Crinetics Pharmaceuticals expands its pipeline, while analyst consensus remains strongly bullish with an 85.7% buy rating and a $548.78 price target.
Outlook is positive driven by revenue growth and pipeline expansion, but risks include clinical setbacks and competition. The stock offers upside to the consensus target, with cash flow recovery in 2025 signaling operational strength. Investors should weigh high valuation multiples against earnings consistency and market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Taiwan Semiconductor Mfg. Co. Ltd.
Taiwan Semiconductor Manufacturing Company, or TSMC, is the world's largest dedicated chip foundry, with over 57% market share in 2021 per Gartner. TSMC was founded in 1987 as a joint venture of Philips, the government of Taiwan, and private investors. It went public as an ADR in the U.S. in 1997. TSMC's scale and high-quality technology allow the firm to generate solid operating margins, even in the highly competitive foundry business. Furthermore, the shift to the fabless business model has created tailwinds for TSMC. The foundry leader has an illustrious customer base, including Apple, AMD and Nvidia, that looks to apply cutting-edge process technologies to its semiconductor designs.
Read more on TSM →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
